1800-272-662
Shopping Cart 0
countryflagAU
Login

MoonLake Immunotherapeutics

Healthcare US MLTX

17.95USD
-0.39(2.13%)

Last update at 2026-03-11T17:49:00Z

Day Range

17.9119.34
LowHigh

52 Week Range

24.3164.98
LowHigh

Fundamentals

  • Previous Close 18.34
  • Market Cap2621.87M
  • Volume399014
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-60.97934M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-0.73

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Income before tax -43.98473M -64.46968M -4.54265M -0.09084M
Minority interest 6.98M -14.53280M - -
Net income -36.00726M -64.50605M -4.54265M -0.09084M
Selling general administrative 22.32M 23.01M 4.57M -
Selling and marketing expenses 22298.89M - 18.03M -
Gross profit -0.01316M -0.01236M -0.00497M -
Reconciled depreciation 0.01M 0.01M - -
Ebit -54.12310M -65.06142M -4.57034M -
Ebitda -54.10994M -65.04906M -4.57034M -0.10576M
Depreciation and amortization 0.01M 0.01M 0.00497M -
Non operating income net other - 0.59M 0.03M -
Operating income -54.12310M -65.06142M -4.57034M -0.10576M
Other operating expenses 54.12M 65.06M 4.57M 0.11M
Interest expense - 0.59M 0.00000M -
Tax provision 0.06M 0.04M - -
Interest income - - - -
Net interest income - - - -
Extraordinary items - - - -
Non recurring - - - -
Other items - - - -
Income tax expense 0.09M 0.04M 0.00571M -
Total revenue 0.00000M 0.00000M - -
Total operating expenses 54.11M 65.06M 4.57M 0.11M
Cost of revenue 0.01M 0.01M 0.00497M -
Total other income expense net 10.14M 0.59M 0.03M 0.01M
Discontinued operations - - - -
Net income from continuing ops -52.65966M -50.09811M -4.54265M -
Net income applicable to common shares - -49.97325M -4.54265M -
Preferred stock and other adjustments - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Total assets 526.54M 76.84M 9.68M 116.63M
Intangible assets - - - -
Earning assets - - - -
Other current assets 2.10M 4.18M 0.13M 0.28M
Total liab 13.05M 8.08M 21.33M 4.15M
Total stockholder equity 495.68M 48.90M -11.64501M 112.48M
Deferred long term liab - - 4.03M -
Other current liab 8.40M 7.26M 4.66M 0.07M
Common stock 0.00630M 0.00527M 0.04M 115.00M
Capital stock 0.00630M 0.00527M 0.11M -
Retained earnings -116.65747M -80.65021M -53.64361M -2.51662M
Other liab - - 0.24M -
Good will - - - -
Other assets 0.00000M - - -
Cash 451.17M 39.51M 8.04M 1.34M
Cash and equivalents - - - -
Total current liabilities 9.97M 7.67M 21.09M 0.13M
Current deferred revenue -0.18548M - - -
Net debt -447.47147M -39.22305M 6.96M -1.27786M
Short term debt 1.20M 0.15M 15.00M 0.06M
Short long term debt - - 15.00M -
Short long term debt total 3.70M 0.28M 15.00M 0.06M
Other stockholder equity 609.97M 129.19M 42.06M -
Property plant equipment - 0.05M 0.05M -
Total current assets 514.17M 76.51M 9.64M 1.62M
Long term investments - - - -
Net tangible assets - 48.90M 107.94M -
Short term investments 59.84M 32.61M - -
Net receivables 1.06M 0.22M 0.15M -
Long term debt - - - -
Inventory - - 1.32M -
Accounts payable 0.55M 0.25M 1.43M -
Total permanent equity - - - -
Noncontrolling interest in consolidated entity - 19.87M - -
Temporary equity redeemable noncontrolling interests - - - -
Accumulated other comprehensive income 2.36M 0.35M -0.16818M -
Additional paid in capital - - - -
Common stock total equity - 0.00527M 0.00004M -
Preferred stock total equity - - - -
Retained earnings total equity - -80.65021M -7.05927M -
Treasury stock - - - -
Accumulated amortization - - - -
Non currrent assets other 8.42M 0.28M -115.04261M -
Deferred long term asset charges - - - -
Non current assets total 12.37M 0.33M 0.05M 115.01M
Capital lease obligations 3.81M 0.28M - -
Long term debt total - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Investments -132.14959M -32.32458M - -
Change to liabilities - 1.37M 3.80M -
Total cashflows from investing activities - -32.34059M -0.06085M -
Net borrowings - -15.00000M -0.05806M -
Total cash from financing activities 479.70M 119.69M 43.26M 116.65M
Change to operating activities - - 3.68M -
Net income -36.00726M -64.50605M -53.64361M -0.09084M
Change in cash 411.66M 31.47M 6.70M 1.34M
Begin period cash flow 39.51M 8.04M 1.34M -
End period cash flow 451.17M 39.51M 8.04M 1.34M
Total cash from operating activities -42.77817M -55.89390M -35.17519M -0.31669M
Issuance of capital stock 451.29M 451.29M - -
Depreciation 0.01M 0.01M 0.00497M -
Other cashflows from investing activities - - - -
Dividends paid - - 0.05M -
Change to inventory - - - -
Change to account receivables -0.83973M -0.06835M -0.14877M -
Sale purchase of stock - 0.00379M -0.00620M -
Other cashflows from financing activities -2.75292M 134.69M 0.05M -0.34738M
Change to netincome - 9.72M -4.54265M -
Capital expenditures 0.28M 0.02M 0.05M 0.00000M
Change receivables - -0.06835M - -
Cash flows other operating - -2.42634M 0.13M -
Exchange rate changes - - - -
Cash and cash equivalents changes - 31.46M -0.66913M -
Change in working capital -6.21772M -1.42747M 4.48M -0.21594M
Stock based compensation 7.11M 9.65M 0.01M -
Other non cash items 0.30M 0.37M 12.57M -0.00992M
Free cash flow -43.06280M -55.90991M -35.22590M -0.31669M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
MLTX
MoonLake Immunotherapeutics		 -0.39 2.13% 17.95 - - - 5.56 -41.5328
NVO
Novo Nordisk A/S		 0.05 0.13% 38.77 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 0.005 0.01% 38.74 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -7.26 1.45% 491.91 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 6.47 0.84% 778.50 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics

Dorfstrasse 29, Zug, Switzerland, 6300

Key Executives

Name Title Year Born
Dr. Jorge Santos da Silva Co-Founder, CEO & Director 1978
Dr. Kristian Reich Co-Founder & Chief Scientific Officer 1966
Mr. Matthias Bodenstedt Chief Financial Officer 1988
Mr. Oliver Daltrop Chief Technical Officer NA
Ms. Nuala Brennan Chief Clinical Devel. Officer NA
Nicolas Mosimann General Counsel NA
Luciana Marques Director of HR, People & Culture NA
Ms. Nuala Brennan Chief Clinical Development Officer NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.